Navigation Links
Inspire Announces Presentations at Two European Scientific,Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Jun 12, 2007 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that scientists and collaborators related to Inspire will present information at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI) being held June 9-13, 2007 in Goteborg, Sweden and at the 30th European Cystic Fibrosis Society (ECFS) Conference being held June 13-16, 2007 in Belek, Turkey.

The EAACI Congress includes two presentations with clinical data on bilastine, a compound in development by FAES Farma, S.A. for the treatment of allergic rhinitis, which is partnered with Inspire in the United States and Canada, and one presentation with scientific data on epinastine, bilastine and other antihistamines for treating allergies. -0-

-- A Phase 3 Study Comparing the Efficacy and Safety of Once Daily

   Bilastine with Cetirizine and Placebo for the Treatment of Seasonal

   Allergic Rhinitis

   Poster and brief oral presentation on Tuesday, June 12, 2007

-- Treatment with Bilastine Improves Symptoms in Patients with

   Seasonal Allergic Rhinitis (Phase 3 Study Comparing the Efficacy

   and Safety of Once Daily Bilastine with Desloratadine and Placebo

   for the Treatment of Seasonal Allergic Rhinitis)

   Poster and brief oral presentation on Tuesday, June 12, 2007

-- Evaluation of Muscarinic Receptor Antagonism by Antihistamines

   Poster and brief oral presentation on Tuesday, June 12, 2007

The ECFS Conference includes two presentations with clinical data on denufosol, a compound in development by Inspire for the treatment of cystic fibrosis. -0-

-- Deposition and Pharmacokinetic Studies with Inhaled P2Y2 Agonists -

   Evidence of High Lung Delivery and Minimal Systemic Exposure

   Poster presentation on Thursday and Friday, June 14-15, 2007 and

   oral presentation on Thursday, June 14, 2007

-- Reactive Airway Disease and
 Cystic Fibrosis: a Retrospective

   Analysis of the Safety and Tolerability with Denufosol Inhalation


   Poster presentation on Thursday, June 14, 2007 and guided poster

   tour on Friday, June 15, 2007

The posters from these presentations will be available following each related conference on Inspire's website,, in the Research & Development section, under Science & Technology.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(TM) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCI ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are trademarks owned by Allergan, Inc. AzaSite is a trademark owned by InSite Vision Incorporated. For more information, visit

Forward-Looking Statements

The forward-looking statements in this news release relating to management's expectations and beliefs are based on preliminary information and management assumptions. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, s uccess of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof.


Investor Contacts:
Inspire Pharmaceuticals, Inc.
Jenny Kobin,
VP, Investor Relations and Corporate Communications
919-941-9777, Extension 219
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, Extension 14


Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Positive Results of Phase 2 Trial of Epinastine Nasal Spray for Seasonal Allergic Rhinitis
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:10/13/2015)... YORK , Oct. 13, 2015 Pomerantz ... filed against Amicus Therapeutics, Inc. ("Amicus" or the "Company")(NASDAQ: ... filed in United States District Court, District of ... a class consisting of all persons or entities who ... 1, 2015 inclusive (the "Class Period"). This class action seeks ...
(Date:10/13/2015)... , Oct. 13, 2015  Vitamin Angels – ... and mothers in need of nutritional support - announced ... by the United Nations (UN). The UN,s newly established ... – are a recent follow up to the Millennium ... deadline for completion. The new 17 Global Goals intend ...
(Date:10/13/2015)... , Oct. 13, 2015   Generational Equity ... middle-market businesses, is pleased to announce the acquisition of ... in Largo, Florida , by Meridian ... on September 11, 2015. Florida ... --> Florida . To learn ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Hope; A Commitment to Cure last night at the Mandarin Oriental in New ...
(Date:10/13/2015)... — , ... ... Association of America (MOAA) will hold its 2015 annual meeting ... a free military career fair; informational seminars; a luncheon featuring ... the Joint Chiefs of Staff; and the Community Heroes Award ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Vision Group ... Vision of San Diego, California. With brands including The LASIK Vision Institute and TLC ... making it the nationwide leader in laser vision correction. , Global Laser Vision will ...
(Date:10/13/2015)... ... October 13, 2015 , ... PhyMed Healthcare Group , ... its partnership with WPC Healthcare , a provider of predictive analytics solutions ... data into an aggregated data repository necessary to perform reporting and analytics on ...
(Date:10/13/2015)... Texas (PRWEB) , ... October 13, 2015 , ... Symposium ... for the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, ... place immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , ...
Breaking Medicine News(10 mins):